PCM
ALDX icon

Prelude Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Prelude Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,413
Closed -$14K – 1778
2020
Q2 		$14K Buy
+3,413
New +$12.5K ﹤0.01% 1481
2020
Q1 		– Sell
-1,840
Closed -$11K – 1394
2019
Q4 		$11K Sell
1,840
-320
-15% -$1.85K ﹤0.01% 1685
2019
Q3 		$11K Sell
2,160
-260
-11% -$1.4K ﹤0.01% 1479
2019
Q2 		$15K Sell
2,420
-160
-6% -$1.2K ﹤0.01% 1328
2019
Q1 		$23K Buy
2,580
+8
+0.3% +$68 ﹤0.01% 1292
2018
Q4 		$21K Sell
2,572
-1,500
-37% -$15.4K ﹤0.01% 1233
2018
Q3 		$56K Sell
4,072
-17,343
-81% -$141K ﹤0.01% 1101
2018
Q2 		$170K Buy
21,415
+18,684
+684% +$149K 0.01% 788
2018
Q1 		$20K Buy
2,731
+1,378
+102% +$10.5K ﹤0.01% 1260
2017
Q4 		$9K Sell
1,353
-11
-0.8% -$72 ﹤0.01% 1211
2017
Q3 		$10K Sell
1,364
-1,087
-44% -$5.68K ﹤0.01% 1428
2017
Q2 		$11K Buy
+2,451
New +$11.3K ﹤0.01% 1374

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Prelude Capital Management's ALDX Position: Q3 2020 in Review

Prelude Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2020, closing a stake of 3,413 shares — an estimated $14K sold.

Prelude Capital Management first reported a position in ALDX in Q2 2017 and held it in 12 quarters. The position peaked at $170K in Q2 2018. 87 funds tracked by Wall St. Rank hold ALDX as of Q3 2020.

  • Prelude Capital Management reported no remaining Aldeyra Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 3,413 Aldeyra Therapeutics shares in Q3 2020, an estimated $14K.
  • Prelude Capital Management first reported a position in Aldeyra Therapeutics in Q2 2017 and held it in 12 quarters.
  • Prelude Capital Management's Aldeyra Therapeutics position peaked at $170K in Q2 2018.
  • 87 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.